FDA panel rejects Pfizer's arthritis drug as too risky

By Linda A. Johnson Associated Press

U.S. health advisers sharply criticized an experimental arthritis drug Thursday, saying that it was too risky, even with limits on its use.

The expert panel for the Food and Drug Administration voted 19-1 that the drug’s modest benefits don’t outweigh its considerable risks, even with proposed measures to restrict who gets the medicine. Pfizer is seeking FDA approval of the drug, called tanezumab, to treat pain from mild to moderate arthritis in the hips and knees. It is given by injection every two months.

In studies, a small percentage of participants saw their joint damage get worse faster, sometimes requiring hip or

→ Continue reading at The Spokesman-Review

Related articles


Share article

Latest articles